IOncology

The 29th Chinese Society of Clinical Oncology (CSCO) Annual Meeting was held in Jinan from September 16 to 19, 2026, bringing together leading oncology experts from around the world to explore pathways for innovation and advancement in precision cancer care. Professor Franco Cavalli, President of the International Conference on Malignant Lymphoma (ICML) and Professor at the Oncology Institute of Southern Switzerland in Bellinzona, was invited to attend the meeting and deliver a special presentation. As an internationally renowned expert who has devoted decades to oncology, Professor Cavalli has witnessed more than 30 years of transformation in Chinese oncology since his first visit to China in 1989. In an interview with Oncology Frontier – Hematology Frontier, he reflected on his longstanding exchanges and collaboration with the Chinese oncology community, shared key advances and future directions in extranodal lymphoma, and previewed the major topics to watch at ICML 2027.

The Pujiang Prostate Cancer Academic Conference was recently held in Shanghai. Under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration,” the conference provided a high-level platform for academic exchange, focusing on key topics including early screening and precision diagnosis of prostate cancer, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care systems. By fostering deeper integration between clinical practice and cutting-edge research, the conference aimed to further advance the standard of prostate cancer care in China.

The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. The rapid development of antibody–drug conjugates (ADCs) and immunotherapy is moving the treatment of urothelial carcinoma beyond later-line advanced disease to first-line treatment, the perioperative setting, and even non-muscle-invasive disease. At the same time, the clinical introduction of ADCs with multiple targets and payloads has raised new challenges, including treatment sequencing, cross-resistance, and cumulative toxicity. Oncology Frontier – UroStream invited Professor Xiaojie Bian of Fudan University Shanghai Cancer Center for an interview to discuss the earlier use of ADCs, sequencing strategies, perioperative investigations, and comprehensive safety management throughout the treatment continuum.

Precise suturing is a key foundation for high-quality reconstruction in minimally invasive surgery. During laparoscopic radical prostatectomy, vesicourethral anastomosis tests the surgeon's ability to control needle-holding angles and needle trajectories, while directly affecting procedural stability and reproducibility. In this interview, Oncology Frontier – UroStream invited Professor Zhenghua Ju of Fujian Cancer Hospital to discuss the technical challenges of laparoscopic vesicourethral anastomosis, the evolution of the 360° suturing theory into the “Three Fundamental Principles of Surgical Suturing,” and the clinical value of standardized dissemination and training.

The 2026 Pujiang Prostate Cancer Academic Conference was successfully held in Shanghai under the central theme of “Standardization, Precision Breakthroughs, Chinese Innovation, and Global Collaboration.” The conference aimed to promote the standardized diagnosis and treatment of prostate cancer in China while advancing key technological innovations. Following the meeting, Oncology Frontier – UroStream invited Professor Hongkai Wang of Fudan University Shanghai Cancer Center to discuss recent innovations in robotic radical prostatectomy, balancing oncological control with functional preservation, and the development of domestically developed surgical robots.

Treatment decisions for advanced renal cell carcinoma (RCC) are shifting from traditional clinical risk stratification toward precision classification based on molecular characteristics. What is the scientific rationale behind this trend? Which key molecular biomarkers hold the greatest promise for guiding treatment selection and sequencing? And what are the major obstacles to translating scientific discoveries in precision medicine into clinical practice?

Approximately 101,000 new cases of bladder cancer are diagnosed annually in China, making it the 11th most common malignancy. The disease is more prevalent in southern China than in the north, and its incidence is trending toward younger age groups. Meanwhile, high-risk localized or locally advanced prostate cancer carries a substantial risk of biochemical recurrence and distant metastasis, and local treatment alone is often insufficient to address the full spectrum of clinical needs.

The “Gaobo Medical Forum—6th Shanghai Clinical Application Seminar on Hematopoietic Stem Cell Transplantation and Training Course on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation,” hosted by the National Clinical Research Center for Hematologic Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Shanghai Zhaxin Hospital/Gaobo Medical Group and Shanghai Liquan Hospital, was held in Shanghai on August 29–30, 2026. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Dehui Zou of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss optimization and alternative strategies for conditioning regimens in autologous hematopoietic stem cell transplantation (ASCT) for lymphoma. Against the backdrop of increasingly diverse novel therapies, Professor Zou explored the precise positioning and clinical value of ASCT, as well as the integration of innovative therapies such as CAR-T with conventional transplantation, and shared insights into future directions.

The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. In recent years, the rapid development of antibody-drug conjugates (ADCs) and immunotherapy has reshaped the first-line treatment landscape for locally advanced or metastatic urothelial carcinoma (LA/mUC), while closer coordination among systemic therapy, surgery, and long-term follow-up has become increasingly important. Although emerging evidence has provided patients with more treatment options, challenges remain in pretreatment assessment, adverse event management, response evaluation, and long-term follow-up, with the ultimate goal of translating advances from clinical research into sustained real-world benefits. During the conference, Oncology Frontier · UroStream invited Professor Yiping Zhu from Fudan University Shanghai Cancer Center to share his perspectives on first-line treatment innovation, perioperative systemic therapy, the evolving role of surgery, and advances in molecular monitoring.

The rapid development of antibody-drug conjugates (ADCs) and immunotherapy is driving bladder-preservation strategies beyond single-modality local treatment toward an integrated approach combining systemic therapy, local treatment, and molecular stratification. Oncology Frontier – UroStream invited Professor Yijun Shen of Fudan University Shanghai Cancer Center to discuss combination bladder-preservation strategies for high-risk non-muscle-invasive bladder cancer (NMIBC), the implications of perioperative studies in muscle-invasive bladder cancer (MIBC) for traditional treatment pathways, and the potential applications of biomarkers such as circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA).